RobertArthurKratzkeMD
Oncology • Minneapolis, MNThoracic Cancer
Professor, Medicine, University of Minnesota Medical School
Dr. Kratzke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
424 Harvard St Se
Masonic Cancer Center, First Floor, Suite M100
Minneapolis, MN 55455Phone+1 612-625-5411- Is this information wrong?
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1983 - 1986
University of Washington School of MedicineClass of 1983
Certifications & Licensure
WI State Medical License 1984 - 2025
MN State Medical License 1998 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers Start of enrollment: 2008 Dec 01
- Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107 Start of enrollment: 2005 Nov 01
Publications & Presentations
PubMed
- Cancer sensitizing effect of deazaflavin analogs is associated with increased intracellular drug accumulation.Belhadj, Z., Offei, S., Jacobson, B., Cambron, D., Wang, Z., Xie, J., Kratzke, R.> ;European Journal of Pharmaceutical Sciences. 2024 Feb 1
- SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer.Libang Yang, Adam Gilbertsen, Blake Jacobson, Jenny Pham, Naomi Fujioka, Craig A Henke, Robert A Kratzke> ;International Journal of Molecular Sciences. 2023 Aug 6
- 4 citationsA tri-specific killer engager against mesothelin targets NK cells towards lung cancer.Philippa R Kennedy, Daniel A Vallera, Brianna Ettestad, Caroline Hallstrom, Behiye Kodal, Deborah A Todhunter, Laura Bendzick, Peter Hinderlie, Joshua T Walker, Britta...> ;Frontiers in Immunology. 2023 Jan 1
- Join now to see all
Journal Articles
- LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry Based Biomarkers in Resected Non-Small Cell Lung CancerRobert Kratzke, MD, Clinical Lung Cancer
Press Mentions
OncLive® Presents State of the Science Summit™ on Lung CancerAugust 1st, 2019
Masonic Cancer Center Professor Elected Chair of the Big Ten Cancer Research Consortium Steering CommitteeDecember 23rd, 2016
Grant Support
- Protocol Review &Monitoring SystemNational Cancer Institute2009–2012
- CDK Inhibitors And Response To DHAC In MesotheliomaNational Cancer Institute2000–2001
Professional Memberships
- Member
Hospital Affiliations
M Health Fairview University of Minnesota Medical CenterMinneapolis, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
